• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

采用中心复合设计法对盐酸普萘洛尔微胶囊进行处方优化

Formulation optimization of propranolol hydrochloride microcapsules employing central composite design.

作者信息

Shivakumar H N, Patel R, Desai B G

机构信息

Department of Pharmaceutical Technology, K. L. E. S's College of Pharmacy, Rajajinagar, 2 Block, Bangalore-560 010, India.

出版信息

Indian J Pharm Sci. 2008 May-Jun;70(3):408-13. doi: 10.4103/0250-474X.43024.

DOI:10.4103/0250-474X.43024
PMID:20046763
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2792503/
Abstract

A central composite design was employed to produce microcapsules of propranolol hydrochloride by o/o emulsion solvent evaporation technique using a mixture of cellulose acetate butyrate as coat material and span-80 as an emulsifier. The effect of formulation variables namely levels of cellulose acetate butyrate (X(1)) and percentage of Span-80 (X(2)) on encapsulation efficiency (Y(1)), drug release at the end of 1.5 h (Y(2)), 4 h (Y(3)), 8 h (Y(4)), 14 h (Y(5)), and 24 h (Y(6)) were evaluated using the F test. Mathematical models containing only the significant terms were generated for each response parameter using multiple linear regression analysis and analysis of variance. Both the formulation variables exerted a significant influence (P <0.05) on Y(1) whereas the cellulose acetate butyrate level emerged as the lone factor which significantly influenced the other response parameters. Numerical optimization using desirability approach was employed to develop an optimized formulation by setting constraints on the dependent and independent variables. The experimental values of Y(1), Y(2), Y(3), Y(4), Y(5), and Y(6) for the optimized formulation was found to be 92.86+/-1.56% w/w, 29.58+/-1.22%, 48.56+/-2.56%, 60.85+/-2.35%, 76.23+/-3.16% and 95.12+/-2.41%, respectively which were in close agreement with those predicted by the mathematical models. The drug release from microcapsules followed first order kinetics and was characterized by Higuchi diffusion model. The optimized microcapsule formulation developed was found to comply with the USP drug release test-1 for extended release propranolol hydrochloride capsules.

摘要

采用中心复合设计,以醋酸丁酸纤维素混合物为包衣材料、司盘 - 80为乳化剂,通过油/油乳液溶剂蒸发技术制备盐酸普萘洛尔微胶囊。使用F检验评估配方变量即醋酸丁酸纤维素水平(X(1))和司盘 - 80百分比(X(2))对包封率(Y(1))、1.5小时末(Y(2))、4小时(Y(3))、8小时(Y(4))、14小时(Y(5))和24小时(Y(6))药物释放的影响。使用多元线性回归分析和方差分析为每个响应参数生成仅包含显著项的数学模型。两个配方变量对Y(1)均有显著影响(P <0.05),而醋酸丁酸纤维素水平是显著影响其他响应参数的唯一因素。采用合意性方法进行数值优化,通过对因变量和自变量设置约束来开发优化配方。发现优化配方的Y(1)、Y(2)、Y(3)、Y(4)、Y(5)和Y(6)的实验值分别为92.86±1.56% w/w、29.58±1.22%、48.56±2.56%、60.85±2.35%、76.23±3.16%和95.12±2.41%,与数学模型预测值非常吻合。微胶囊的药物释放遵循一级动力学,并以Higuchi扩散模型为特征。所开发的优化微胶囊配方符合美国药典盐酸普萘洛尔缓释胶囊的药物释放试验 - 1。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bac0/2792503/9c4bec9d47f0/IJPhS-70-408-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bac0/2792503/9c4bec9d47f0/IJPhS-70-408-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bac0/2792503/9c4bec9d47f0/IJPhS-70-408-g001.jpg

相似文献

1
Formulation optimization of propranolol hydrochloride microcapsules employing central composite design.采用中心复合设计法对盐酸普萘洛尔微胶囊进行处方优化
Indian J Pharm Sci. 2008 May-Jun;70(3):408-13. doi: 10.4103/0250-474X.43024.
2
Formulation Optimization of Human Insulin Loaded Microspheres for Controlled Oral Delivery Using Response Surface Methodology.采用响应面法对用于口服控释的载有人胰岛素微球进行制剂优化。
Endocr Metab Immune Disord Drug Targets. 2017;17(2):149-165. doi: 10.2174/1871530317666170503120129.
3
Design and optimization of diclofenac sodium controlled release solid dispersions by response surface methodology.采用响应面法设计与优化双氯芬酸钠控释固体分散体
Indian J Pharm Sci. 2008 Jan;70(1):22-30. doi: 10.4103/0250-474X.40327.
4
Design and statistical optimization of glipizide loaded lipospheres using response surface methodology.使用响应面法对格列吡嗪载药脂质球进行设计与统计优化。
Acta Pharm. 2007 Sep;57(3):269-85. doi: 10.2478/v10007-007-0022-8.
5
Peculiar effect of polyethylene glycol in comparison with triethyl citrate or diethyl phthalate on properties of ethyl cellulose microcapsules containing propranolol hydrochloride in process of emulsion-solvent evaporation.聚乙二醇相较于柠檬酸三乙酯或邻苯二甲酸二乙酯,在乳液-溶剂蒸发过程中对含盐酸普萘洛尔的乙基纤维素微胶囊性能的特殊影响。
Drug Dev Ind Pharm. 2018 Mar;44(3):421-431. doi: 10.1080/03639045.2017.1395460. Epub 2017 Nov 8.
6
Microencapsulation of ketoprofen using w/o/w complex emulsion technique.采用水包油包水复合乳液技术对酮洛芬进行微囊化。
J Microencapsul. 1996 Jan-Feb;13(1):67-87. doi: 10.3109/02652049609006804.
7
Functionalization of chitosan/methylcellulose interpenetrating polymer network microspheres for gastroretentive application using central composite design.采用中心复合设计法制备用于胃滞留应用的壳聚糖/甲基纤维素互穿聚合物网络微球的功能化
PDA J Pharm Sci Technol. 2010 Nov-Dec;64(6):497-506.
8
Mucoadhesive microparticulate drug delivery system of curcumin against Helicobacter pylori infection: Design, development and optimization.姜黄素抗幽门螺杆菌感染的黏膜黏附微粒给药系统:设计、开发与优化。
J Adv Pharm Technol Res. 2014 Jan;5(1):48-56. doi: 10.4103/2231-4040.126996.
9
Sustained release of propranolol hydrochloride based on ion-exchange resin entrapped within polystyrene microcapsules.基于包裹在聚苯乙烯微胶囊内的离子交换树脂实现盐酸普萘洛尔的缓释。
J Microencapsul. 2006 Dec;23(8):899-911. doi: 10.1080/02652040601035192.
10
Development and optimization of a novel sustained-release dextran tablet formulation for propranolol hydrochloride.新型盐酸普萘洛尔缓释右旋糖酐片剂制剂的研发与优化
Int J Pharm. 2006 Jul 6;317(1):32-9. doi: 10.1016/j.ijpharm.2006.02.049. Epub 2006 Apr 11.

本文引用的文献

1
Characterization of biodegradable chitosan microspheres containing vancomycin and treatment of experimental osteomyelitis caused by methicillin-resistant Staphylococcus aureus with prepared microspheres.含万古霉素的可生物降解壳聚糖微球的表征及用制备的微球治疗耐甲氧西林金黄色葡萄球菌引起的实验性骨髓炎
Int J Pharm. 2006 Jul 24;317(2):127-35. doi: 10.1016/j.ijpharm.2006.03.014. Epub 2006 Apr 19.
2
Incorporation of a model protein into chitosan-bile salt microparticles.将一种模型蛋白掺入壳聚糖-胆盐微粒中。
Int J Pharm. 2006 Apr 7;312(1-2):119-30. doi: 10.1016/j.ijpharm.2006.01.006. Epub 2006 Feb 9.
3
Development of three layered buccal compact containing metoprolol tartrate by statistical optimization technique.
采用统计优化技术研制含酒石酸美托洛尔的三层颊用速溶片。
Int J Pharm. 2005 Nov 4;304(1-2):102-14. doi: 10.1016/j.ijpharm.2005.07.021. Epub 2005 Sep 16.
4
New drug salt formation in biodegradable microspheres.可生物降解微球中的新型药物盐形成
Int J Pharm. 2005 Oct 13;303(1-2):153-9. doi: 10.1016/j.ijpharm.2005.06.029.
5
Dose adjustment in renal impairment: response from Martindale: the Complete Drug Reference.肾功能损害时的剂量调整:《马丁代尔药物大典》的回应
BMJ. 2005 Jul 30;331(7511):292-3. doi: 10.1136/bmj.331.7511.292-a.
6
Observations in simultaneous microencapsulation of 5-fluorouracil and leucovorin for combined pH-dependent release.5-氟尿嘧啶和亚叶酸同时微囊化以实现联合pH依赖性释放的观察结果。
Eur J Pharm Biopharm. 2005 Feb;59(2):367-71. doi: 10.1016/j.ejpb.2004.09.005.
7
Effect of formulation and processing variables on the characteristics of microspheres for water-soluble drugs prepared by w/o/o double emulsion solvent diffusion method.制剂和工艺变量对采用水包油包水双乳液溶剂扩散法制备的水溶性药物微球特性的影响。
Int J Pharm. 2000 Feb 25;196(1):75-83. doi: 10.1016/s0378-5173(99)00440-8.
8
Peroral sustained-release film-coated pellets as a means to overcome physicochemical and biological drug-related problems. I. In vitro development and evaluation.口服缓释薄膜包衣微丸作为克服药物相关物理化学和生物学问题的一种手段。I. 体外研发与评价。
Drug Dev Ind Pharm. 1998 Jun;24(6):509-15. doi: 10.3109/03639049809085651.
9
Design of a new multiparticulate system for potential site-specific and controlled drug delivery to the colonic region.一种新型多颗粒系统的设计,用于实现向结肠区域的潜在位点特异性和可控药物递送。
J Control Release. 1998 Oct 30;55(1):67-77. doi: 10.1016/s0168-3659(98)00029-7.